vs
碧迪（BDX）与United Rentals（URI）财务数据对比。点击上方公司名可切换其他公司
碧迪的季度营收约是United Rentals的1.3倍（$5.3B vs $4.0B），United Rentals净利率更高（13.3% vs 7.3%，领先6.1%），United Rentals同比增速更快（7.2% vs -0.4%），United Rentals自由现金流更多（$1.1B vs $549.0M），过去两年United Rentals的营收复合增速更高（114.0% vs 2.0%）
碧迪（Becton Dickinson）是美国跨国医疗科技企业，核心业务包括研发、生产及销售医用器械、仪器系统与试剂产品，同时在特定领域提供专业咨询及数据分析服务，业务覆盖全球多国，在全球医疗技术领域具备领先地位。
United Rentals是美国设备租赁企业，2022年占据北美市场约16%的份额。截至2025年，该公司拥有全球规模最大的租赁车队，覆盖约4800类设备，原始设备成本总计约205.9亿美元，在全球共设1625个营业网点，业务覆盖北美、欧洲、澳大利亚及新西兰。
BDX vs URI — 直观对比
营收规模更大
BDX
是对方的1.3倍
$4.0B
营收增速更快
URI
高出7.5%
-0.4%
净利率更高
URI
高出6.1%
7.3%
自由现金流更多
URI
多$505.0M
$549.0M
两年增速更快
URI
近两年复合增速
2.0%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $5.3B | $4.0B |
| 净利润 | $382.0M | $531.0M |
| 毛利率 | 45.9% | 36.9% |
| 营业利润率 | 10.5% | 21.8% |
| 净利率 | 7.3% | 13.3% |
| 营收同比 | -0.4% | 7.2% |
| 净利润同比 | 24.0% | 2.5% |
| 每股收益（稀释后） | $1.34 | $8.43 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDXURI
| Q1 26 | — | $4.0B | ||
| Q4 25 | $5.3B | $992.0M | ||
| Q3 25 | $5.9B | $938.0M | ||
| Q2 25 | $5.5B | $872.0M | ||
| Q1 25 | $5.3B | $893.0M | ||
| Q4 24 | $5.2B | $1.0B | ||
| Q3 24 | $5.4B | $874.0M | ||
| Q2 24 | $5.0B | $870.0M |
净利润BDXURI
| Q1 26 | — | $531.0M | ||
| Q4 25 | $382.0M | $653.0M | ||
| Q3 25 | $493.0M | $701.0M | ||
| Q2 25 | $574.0M | $622.0M | ||
| Q1 25 | $308.0M | $518.0M | ||
| Q4 24 | $303.0M | $689.0M | ||
| Q3 24 | $400.0M | $708.0M | ||
| Q2 24 | $487.0M | $636.0M |
毛利率BDXURI
| Q1 26 | — | 36.9% | ||
| Q4 25 | 45.9% | — | ||
| Q3 25 | 47.5% | — | ||
| Q2 25 | 47.8% | — | ||
| Q1 25 | 42.8% | — | ||
| Q4 24 | 43.2% | — | ||
| Q3 24 | 45.7% | — | ||
| Q2 24 | 46.2% | — |
营业利润率BDXURI
| Q1 26 | — | 21.8% | ||
| Q4 25 | 10.5% | — | ||
| Q3 25 | 11.8% | — | ||
| Q2 25 | 16.0% | — | ||
| Q1 25 | 10.4% | 90.0% | ||
| Q4 24 | 8.8% | — | ||
| Q3 24 | 11.4% | — | ||
| Q2 24 | 12.1% | — |
净利率BDXURI
| Q1 26 | — | 13.3% | ||
| Q4 25 | 7.3% | 65.8% | ||
| Q3 25 | 8.4% | 74.7% | ||
| Q2 25 | 10.4% | 71.3% | ||
| Q1 25 | 5.8% | 58.0% | ||
| Q4 24 | 5.9% | 67.6% | ||
| Q3 24 | 7.4% | 81.0% | ||
| Q2 24 | 9.8% | 73.1% |
每股收益（稀释后）BDXURI
| Q1 26 | — | $8.43 | ||
| Q4 25 | $1.34 | $10.20 | ||
| Q3 25 | $1.71 | $10.91 | ||
| Q2 25 | $2.00 | $9.59 | ||
| Q1 25 | $1.07 | $7.91 | ||
| Q4 24 | $1.04 | $10.41 | ||
| Q3 24 | $1.37 | $10.70 | ||
| Q2 24 | $1.68 | $9.54 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $740.0M | $156.0M |
| 总债务越低越好 | — | $13.9B |
| 股东权益账面价值 | $25.3B | $9.0B |
| 总资产 | $54.8B | $29.9B |
| 负债/权益比越低杠杆越低 | — | 1.55× |
8季度趋势，按日历期对齐
现金及短期投资BDXURI
| Q1 26 | — | $156.0M | ||
| Q4 25 | $740.0M | $459.0M | ||
| Q3 25 | $641.0M | $512.0M | ||
| Q2 25 | $735.0M | $548.0M | ||
| Q1 25 | $667.0M | $542.0M | ||
| Q4 24 | $711.0M | $457.0M | ||
| Q3 24 | $1.7B | $479.0M | ||
| Q2 24 | $4.5B | $467.0M |
总债务BDXURI
| Q1 26 | — | $13.9B | ||
| Q4 25 | — | $12.7B | ||
| Q3 25 | — | $12.6B | ||
| Q2 25 | — | $12.1B | ||
| Q1 25 | — | $11.5B | ||
| Q4 24 | — | $12.2B | ||
| Q3 24 | — | $11.9B | ||
| Q2 24 | — | $11.5B |
股东权益BDXURI
| Q1 26 | — | $9.0B | ||
| Q4 25 | $25.3B | $9.0B | ||
| Q3 25 | $25.4B | $9.0B | ||
| Q2 25 | $25.5B | $9.0B | ||
| Q1 25 | $25.2B | $8.8B | ||
| Q4 24 | $25.2B | $8.6B | ||
| Q3 24 | $25.9B | $8.6B | ||
| Q2 24 | $25.9B | $8.3B |
总资产BDXURI
| Q1 26 | — | $29.9B | ||
| Q4 25 | $54.8B | $29.9B | ||
| Q3 25 | $55.3B | $30.1B | ||
| Q2 25 | $54.9B | $29.2B | ||
| Q1 25 | $54.5B | $28.1B | ||
| Q4 24 | $54.7B | $28.2B | ||
| Q3 24 | $57.3B | $28.4B | ||
| Q2 24 | $55.6B | $27.6B |
负债/权益比BDXURI
| Q1 26 | — | 1.55× | ||
| Q4 25 | — | 1.41× | ||
| Q3 25 | — | 1.40× | ||
| Q2 25 | — | 1.34× | ||
| Q1 25 | — | 1.31× | ||
| Q4 24 | — | 1.42× | ||
| Q3 24 | — | 1.38× | ||
| Q2 24 | — | 1.39× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $657.0M | $1.5B |
| 自由现金流经营现金流 - 资本支出 | $549.0M | $1.1B |
| 自由现金流率自由现金流/营收 | 10.5% | 26.4% |
| 资本支出强度资本支出/营收 | 2.1% | — |
| 现金转化率经营现金流/净利润 | 1.72× | 2.85× |
| 过去12个月自由现金流最近4个季度 | $2.6B | — |
8季度趋势，按日历期对齐
经营现金流BDXURI
| Q1 26 | — | $1.5B | ||
| Q4 25 | $657.0M | $1.3B | ||
| Q3 25 | $1.4B | $1.2B | ||
| Q2 25 | $1.2B | $1.3B | ||
| Q1 25 | $164.0M | $1.4B | ||
| Q4 24 | $693.0M | $1.0B | ||
| Q3 24 | $1.2B | $1.2B | ||
| Q2 24 | $1.3B | $1.3B |
自由现金流BDXURI
| Q1 26 | — | $1.1B | ||
| Q4 25 | $549.0M | — | ||
| Q3 25 | $1.0B | — | ||
| Q2 25 | $1.0B | — | ||
| Q1 25 | $35.0M | — | ||
| Q4 24 | $588.0M | $471.0M | ||
| Q3 24 | $882.0M | $-168.0M | ||
| Q2 24 | $1.1B | $-263.0M |
自由现金流率BDXURI
| Q1 26 | — | 26.4% | ||
| Q4 25 | 10.5% | — | ||
| Q3 25 | 17.0% | — | ||
| Q2 25 | 19.0% | — | ||
| Q1 25 | 0.7% | — | ||
| Q4 24 | 11.4% | 46.2% | ||
| Q3 24 | 16.2% | -19.2% | ||
| Q2 24 | 22.4% | -30.2% |
资本支出强度BDXURI
| Q1 26 | — | — | ||
| Q4 25 | 2.1% | — | ||
| Q3 25 | 6.0% | — | ||
| Q2 25 | 3.2% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 2.0% | 56.6% | ||
| Q3 24 | 5.4% | 157.0% | ||
| Q2 24 | 3.6% | 175.6% |
现金转化率BDXURI
| Q1 26 | — | 2.85× | ||
| Q4 25 | 1.72× | 1.92× | ||
| Q3 25 | 2.75× | 1.68× | ||
| Q2 25 | 2.12× | 2.14× | ||
| Q1 25 | 0.53× | 2.75× | ||
| Q4 24 | 2.29× | 1.52× | ||
| Q3 24 | 2.94× | 1.70× | ||
| Q2 24 | 2.66× | 1.99× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
URI
| Equipment rentals | $3.4B | 86% |
| Sales of rental equipment | $350.0M | 9% |
| Service and other revenues | $92.0M | 2% |
| Sales of new equipment | $84.0M | 2% |
| Contractor supplies sales | $40.0M | 1% |
